Drug Trial Radar · NCT05374512
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
644
Actual
Start
May 16, 2022
Primary completion
Aug 25, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- May 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
Conditions
- Breast Cancer
Interventions
Dato-DXdDrug
Experimental drug. Provided in 100mg vials. IV infusion.
PaclitaxelDrug
IV Infusion. Active comparator
Nab-paclitaxelDrug
IV infusion. Active comparator
CarboplatinDrug
IV infusion. Active comparator
CapecitabineDrug
Tablet. Oral route of administration. Active comparator
Eribulin mesylateDrug
IV infusion. Active comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From randomization until progression as assessed by BICR or death due to any cause (anticipated to be up to 26 months)
- Overall Survival (OS)Time frame: From randomisation until the date of death due to any cause (approximately 42 months)
Locations
228 sites in 23 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California
Research Site
Los Angeles, California
Research Site
San Francisco, California
Research Site
Grand Junction, Colorado
Research Site
Longmont, Colorado
Research Site
New Haven, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Atlanta, Georgia
Research Site
Louisville, Kentucky
Research Site
Detroit, Michigan
Research Site
Albuquerque, New Mexico
Research Site
New York, New York
Research Site
Charlotte, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Providence, Rhode Island
Research Site
Sioux Falls, South Dakota
Research Site
Memphis, Tennessee
Research Site
Nashville, Tennessee
Research Site
Fort Worth, Texas
Research Site
Houston, Texas
Research Site
Kingwood, Texas
Research Site
San Antonio, Texas
Research Site
Charlottesville, Virginia
Research Site
Spokane Valley, Washington
Research Site
Madison, Wisconsin
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad Autónoma Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Anderlecht, Belgium
Research Site
Ghent, Belgium
Research Site
Namur, Belgium
Research Site
Sint-Niklaas, Belgium
Research Site
Wilrijk, Belgium
Showing 40 of 228 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.